Is tepotinib a targeted drug? Which generation does it belong to?

Tepotinib (tepotinib) is a targeted drug that belongs to the third generation tyrosine kinase inhibitor (TKI). has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced non-small cell lung cancer containing MET mutations. This inhibitor is highly potent, selective, and has central nervous system penetrating activity, a new generation inhibitor with higher selectivity and targeting.

Tepotinib mainly targets tumors with MET gene abnormalities, especially MET fusion gene-positive tumors. Compared with earlier TKIs, third-generation TKIs act on targets more precisely and can reduce adverse effects on normal cells. Tepotinib also showed partial responses in half of patients with advanced non-small cell lung cancer harboring MET exon 14 skipping mutations. The median age of patients with non-small cell lung cancer with MET exon 14 mutations is 72.5 years old, 36% of patients with MET exon 14 mutations have never smoked, and 68% are female.

The original drug Tepotinib is a new type of drug that has not yet been marketed in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug in pharmacies or hospitals. The price of Tepotinib's original drug specification 225mg*30 tablets per box is around RMB 80,000 per box (the price may fluctuate due to exchange rate effects). It has been on the market for a short time and is expensive. There are also generic Tepotinib drugs produced in other countries. The price of a box of 225mg*60 tablets produced by a Lao pharmaceutical factory is around RMB 8,600 (the price may fluctuate due to the exchange rate). The ingredients of generic drugs produced abroad are basically the same as those of the original drug. For specific prices and drug details, please consult Yaode’s medical consultant.